| Nicotine as a potential neuroprotective agent for Parkinson's disease M Quik, XA Perez, T Bordia Movement disorders 27 (8), 947-957, 2012 | 284 | 2012 |
| Multiple roles for nicotine in Parkinson's disease M Quik, LZ Huang, N Parameswaran, T Bordia, C Campos, XA Perez Biochemical pharmacology 78 (7), 677-685, 2009 | 182 | 2009 |
| Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates M Quik, N Parameswaran, SE McCallum, T Bordia, S Bao, A McCormack, ... Journal of neurochemistry 98 (6), 1866-1875, 2006 | 148 | 2006 |
| Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease T Bordia, C Campos, L Huang, M Quik Journal of Pharmacology and Experimental Therapeutics 327 (1), 239-247, 2008 | 136 | 2008 |
| Nicotinic receptors as CNS targets for Parkinson's disease M Quik, T Bordia, K O’Leary Biochemical pharmacology 74 (8), 1224-1234, 2007 | 129 | 2007 |
| Including garlic in the diet may help lower blood glucose, cholesterol, and triglycerides M Thomson, KK Al-Qattan, T Bordia, M Ali The Journal of nutrition 136 (3), 800S-802S, 2006 | 127 | 2006 |
| Nigrostriatal damage preferentially decreases a subpopulation of α6β2* nAChRs in mouse, monkey, and Parkinson's disease striatum T Bordia, SR Grady, JM McIntosh, M Quik Molecular pharmacology 72 (1), 52-61, 2007 | 121 | 2007 |
| Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease M Quik, D Zhang, M McGregor, T Bordia Biochemical pharmacology 97 (4), 399-407, 2015 | 117 | 2015 |
| Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias T Bordia, XA Perez, JE Heiss, D Zhang, M Quik Neurobiology of disease 91, 47-58, 2016 | 84 | 2016 |
| Nicotine and nicotinic receptor drugs: potential for Parkinson's disease and drug-induced movement disorders M Quik, T Bordia, D Zhang, XA Perez International review of neurobiology 124, 247-271, 2015 | 81 | 2015 |
